Overview

Colecalciferol as an Add-on Treatment to Subcutaneously-Administered Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)

Status:
Completed

Trial end date:
2011-08-01

Target enrollment:

Participant gender:

Summary

This is a one-year multi-centre, double blind, placebo controlled, randomized trial investigating oral vitamin D3 (Colecalciferol) as an add-on treatment to interferon-beta-1b for Multiple Sclerosis (MS). Not less than one month after initiation of therapy with interferon beta 1b, MS patients will be randomised to once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 0.5 mg of vitamin D3, or to once weekly peroral treatment with matching placebo. The hypothesis is that vitamin D suppresses clinical and MRI activity of MS.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

University of Turku

Collaborator:

Bayer

Treatments:

Cholecalciferol
Interferon beta-1b
Interferon-beta
Interferons
Vitamin D
Vitamins